Zero Revenue, Net Loss for Exousia Bio in Q3; Strategic Biotech Pivot Underway
Summary
Exousia Bio reported Q3 2026 results with $0 revenue and a net loss of $19,083. This follows the 10-Q filing on the same day, which disclosed a going concern warning, no cash, and a past-due $250,000 convertible note with highly dilutive terms. The company has completed a strategic pivot to a clinical-stage exosome oncology business, ceasing prior education-related revenue. These results confirm the company's severe financial distress and the very early, non-revenue generating stage of its new biotech venture.
At the time of this announcement, LMMY was trading at $0.44 on OTC in the Life Sciences sector. The 52-week trading range was $0.06 to $16.00. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.